This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

3 Contrarian Stocks Einhorn Just Bought

BOSTON ( TheStreet) -- David Einhorn, manager of long-short hedge fund Greenlight Capital, held a concentrated portfolio of 38 stocks at the end of the first quarter. Greenlight has returned upwards of 22% a year since its 1996 inception, underscoring Einhorn's investment acumen. His portfolio underwent a dramatic change during the last quarter.

David Einhorn (Greenlight Capital)

He amplified five positions: Travelers (TRV), Pfizer (PFE), Becton Dickinson (BDX), Microsoft (MSFT) and BioFuel Energy (BIOF).

Einhorn reduced his stakes in 11 stocks, most notably: Ensco (ESV), Cardinal Health (CAH), CIT Group (CIT), CareFusion (CFN) and Transatlantic Holdings (TRH).





He grew even more pessimistic about seven stocks, holdings from the fourth-quarter, which the fund completely sold out of: Everest Re Group (RE), Health Management (HMA), Health Net (HNT), Potash (POT), Verigy (VRGY), Flagstar Bancorp (FBC) and Capitol Federal (CFFND).

In contrast, Einhorn grew particularly bullish on seven stocks during the quarter, building new positions in: AmDocs (DOX - Get Report), Seagate Technology (SKH), HCA Holdings (HCA - Get Report) and CVS Caremark (CVS - Get Report).

Here is a closer look at three more of Einhorn's new positions. These three stocks may be worth consideration for individual investors.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
SKH $8.44 4.46%
BBY $34.37 0.00%
CVS $102.51 0.00%
DOX $55.49 0.00%
HCA $82.39 0.00%

Markets

DOW 18,040.37 +29.69 0.16%
S&P 500 2,111.73 +4.34 0.21%
NASDAQ 5,082.9290 +12.9030 0.25%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs